Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Quabodepistat - Otsuka Pharmaceutical

Next Previous
Drug Profile

Quabodepistat - Otsuka Pharmaceutical

Alternative Names: OPC-167832

Latest Information Update: 15 Oct 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Otsuka Pharmaceutical; Otsuka Pharmaceutical Development & Commercialization
  • Class 2 ring heterocyclic compounds; Antibacterials; Antituberculars; Fluorobenzenes; Piperidines; Small molecules
  • Mechanism of Action DprE1 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Tuberculosis

Most Recent Events

  • 07 Oct 2025 Otsuka Pharmaceutical plans the phase III QUANTUM trial for Tuberculosis (Treatment-resistant, Combination therapy, In adolescents, In adults) in China, Georgia, Japan, Moldova, Peru, Philippines, South Africa, South Korea (PO) (NCT07209761)
  • 19 Sep 2025 Phase-I clinical trials in Tuberculosis in Bulgaria (CTIS2025-521502-18-00)
  • 11 Apr 2025 Efficacy data from a phase I/II trial in Tuberculosis presented at the 35th Congress of the European Society of Clinical Microbiology and Infectious Diseases (ESCMID-2025)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top